1
|
Metelkina-Fernandez V, Dumas LE, Vandersteen C, Chirio D, Gros A, Fernandez A, Askenazy F, Manera V. Psychiatric outcomes in outpatients affected by long COVID: A link between mental health and persistence of olfactory complaint. World J Psychiatry 2024; 14:507-512. [PMID: 38659602 PMCID: PMC11036454 DOI: 10.5498/wjp.v14.i4.507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 01/28/2024] [Accepted: 03/21/2024] [Indexed: 04/17/2024] Open
Abstract
BACKGROUND Anosmia was one of the main symptoms of coronavirus disease 2019 (COVID-19). A psychiatric history (i.e., depression) may be an independent contributor to the risk of COVID-19 diagnosis, and COVID-19 survivors appear to have an increased risk of neuropsychiatric sequelae (bidirectional association). AIM To compare the rate of psychiatric disorder among post-COVID patients without anosmia vs patients with persistent olfactory complaints. METHODS We conducted a prospective case control study from March 2020 to May 2021. Patients recruited at the ENT department of Nice University Hospital had a subjective olfactory complaint (visual analogue scale) for over 6 wk and a molecular or CT-proven severe acute respiratory syndrome coronavirus 2 diagnosis confirmed by serology. Post-COVID patients without persistent olfactory disorders were recruited at the university hospital infectiology department. Psychiatric medical histories were collected by a psychiatrist during the assessments. RESULTS Thirty-four patients with post-COVID-19 olfactory complaints were included in the first group of the study. Fifty percent of the patients were female (n = 17). The group's mean age was 40.5 ± 12.9 years. The control group included 32 participants, of which 34.4% were female (n = 11), and had a mean age of 61.2 ± 12.2 years. The rate of psychiatric disorder among post-COVID patients with olfactory complaints was significatively higher (41.7%) than among patients without (18.8%) (χ2 = 5.9, P = 0.015). CONCLUSION The presence of a psychiatric history may constitute a potential risk factor for the development of long COVID due to persistent anosmia. It therefore seems important to establish reinforced health monitoring after a COVID 19 infection in at-risk patients. Further prospective, translational, and collaborative studies are needed to extrapolate these results to the general population.
Collapse
Affiliation(s)
| | - Louise-Emilie Dumas
- Department of Child and Adolescent Psychiatry, Université Côte d’Azur, Nice 06200, France
| | | | - David Chirio
- Department of Infectiology, Nice University Hospital, Nice 06200, France
| | - Auriane Gros
- Department of Orthophony, Université Côte d’Azur, Nice 06100, France
| | - Arnaud Fernandez
- Department of Child and Adolescent Psychiatry, Université Côte d’Azur, Nice 06200, France
- Cobtek, Université Côte d’Azur, Nice 06100, France
| | - Florence Askenazy
- Department of Child and Adolescent Psychiatry, Université Côte d’Azur, Nice 06200, France
| | | |
Collapse
|
2
|
Chirio D, Demonchy E, Le Marechal M, Gaudart A, Lotte R, Carles M, Ruimy R. 24/7 workflow for bloodstream infection diagnostics in microbiology laboratories: the first step to improve clinical management. Clin Chem Lab Med 2023; 61:349-355. [PMID: 36326696 DOI: 10.1515/cclm-2022-0667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 10/13/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVES We aimed to evaluate the impact of an uninterrupted workflow regarding blood cultures on turnaround time and antibiotic prescription. METHODS Monomicrobial episodes of bacteremia were retrospectively evaluated before and after a continuous 24/7 workflow was implemented in our clinical microbiology laboratory (pre- and post-intervention periods; PREIP and POSTIP). Primary outcome was the time from specimen collection to the first change in antibiotic therapy. Secondary outcomes included the time from specimen collection to effective antibiotic therapy and to antibiotic susceptibility testing results (or turnaround time), as well as hospital length of stay and all-cause mortality at 30 days. RESULTS A total of 548 episodes of bacteremia were included in the final analysis. There was no difference in PREIP and POSTIP regarding patient characteristics and causative bacteria. In POSTIP, the mean time to the first change in antibiotic therapy was reduced by 10.4 h (p<0.001). The time to effective antibiotic therapy and the turnaround time were respectively reduced by 4.8 h (p<0.001) and 5.1 h (p=0.006) in POSTIP. There was no difference in mean hospital length of stay or mortality between the two groups. CONCLUSIONS Around the clock processing of blood cultures allows for a reduction in turnaround time, which in turn reduces the delay until effective antibiotic therapy prescription.
Collapse
Affiliation(s)
- David Chirio
- Service de Maladies infectieuses et Tropicales, Hôpital l'Archet 1, CHU de Nice, Nice, France
- Université Côte d'Azur, Nice, France
| | - Elisa Demonchy
- Service de Maladies infectieuses et Tropicales, Hôpital l'Archet 1, CHU de Nice, Nice, France
| | - Marion Le Marechal
- Service de Maladies infectieuses et Tropicales, Hôpital l'Archet 1, CHU de Nice, Nice, France
- Département de santé publique, CHU de Nice, Nice, France
| | - Alice Gaudart
- Laboratoire de Bactériologie, CHU de Nice, Hôpital de l'Archet, Nice, France
| | - Romain Lotte
- Université Côte d'Azur, Nice, France
- Laboratoire de Bactériologie, CHU de Nice, Hôpital de l'Archet, Nice, France
- INSERM U1065, C3M, Equipe 6 "Virulence microbienne et signalisation inflammatoire", Bâtiment Universitaire Archimed, Nice, France
| | - Michel Carles
- Service de Maladies infectieuses et Tropicales, Hôpital l'Archet 1, CHU de Nice, Nice, France
- Université Côte d'Azur, Nice, France
| | - Raymond Ruimy
- Université Côte d'Azur, Nice, France
- Laboratoire de Bactériologie, CHU de Nice, Hôpital de l'Archet, Nice, France
- INSERM U1065, C3M, Equipe 6 "Virulence microbienne et signalisation inflammatoire", Bâtiment Universitaire Archimed, Nice, France
| |
Collapse
|
3
|
Vandersteen C, Payne M, Dumas LÉ, Cancian É, Plonka A, D’Andréa G, Chirio D, Demonchy É, Risso K, Askenazy-Gittard F, Savoldelli C, Guevara N, Robert P, Castillo L, Manera V, Gros A. Olfactory Training in Post-COVID-19 Persistent Olfactory Disorders: Value Normalization for Threshold but Not Identification. J Clin Med 2022; 11:jcm11123275. [PMID: 35743346 PMCID: PMC9224948 DOI: 10.3390/jcm11123275] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 05/27/2022] [Accepted: 06/05/2022] [Indexed: 02/04/2023] Open
Abstract
(1) Background: Persistent post-viral olfactory disorders (PPVOD) are estimated at 30% of patients one year after COVID-19 infection. No treatment is, to date, significantly effective on PPVOD with the exception of olfactory training (OT). The main objective of this work was to evaluate OT efficiency on post-COVID-19 PPVOD. (2) Methods: Consecutive patients consulting to the ENT department with post-COVID-19 PPVOD were included after completing clinical examination, the complete Sniffin’ Stick Test (TDI), the short version of the Questionnaire of olfactory disorders and the SF-36. Patients were trained to practice a self-olfactory training with a dedicated olfactory training kit twice a day for 6 months before returning to undergo the same assessments. (3) Results: Forty-three patients were included and performed 3.5 months of OT in average. We observed a significant TDI score improvement, increasing from 24.7 (±8.9) before the OT to 30.9 (±9.8) (p < 0.001). Based on normative data, a significant increase in the number of normosmic participants was observed only for the threshold values (p < 0.001). Specific and general olfaction-related quality of life improved after the OT. (4) Conclusions: Olfactory function appeared to improve only in peripheral aspects of post-COVID-19 PPVOD after OT. Future controlled studies must be performed to confirm the OT role and justify new therapeutic strategies that may focus on the central aspects of post-COVID-19 PPVOD.
Collapse
Affiliation(s)
- Clair Vandersteen
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 31 Avenue de Valombrose, 06100 Nice, France; (É.C.); (G.D.); (C.S.); (N.G.); (L.C.)
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Correspondence: ; Tel.: +33-4-9203-1705
| | - Magali Payne
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Département d’Orthophonie de Nice (DON), UFR Médecine, Université Côte d’Azur, 06107 Nice, France
| | - Louise-Émilie Dumas
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Hôpitaux Pédiatriques de Nice CHU-LENVAL, Centre Hospitalier Universitaire, Université Côte d’Azur, 57 Avenue de la Californie, 06200 Nice, France
| | - Élisa Cancian
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 31 Avenue de Valombrose, 06100 Nice, France; (É.C.); (G.D.); (C.S.); (N.G.); (L.C.)
| | - Alexandra Plonka
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Institut NeuroMod, INRIA Centre de Recherche Sophia Antipolis, Université Côte d’Azur, 2004 Route des Lucioles, 06902 Valbonne, France
- Service Clinique Gériatrique du Cerveau et du Mouvement, Centre Hospitalier Universitaire de Nice, 06000 Nice, France
| | - Grégoire D’Andréa
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 31 Avenue de Valombrose, 06100 Nice, France; (É.C.); (G.D.); (C.S.); (N.G.); (L.C.)
| | - David Chirio
- Département de Médecine Infectiologique, Hôpital de l’archet, Centre Hospitalier Universitaire, Université Côte d’Azur, 151 Route de Saint-Antoine, 06200 Nice, France; (D.C.); (É.D.); (K.R.)
| | - Élisa Demonchy
- Département de Médecine Infectiologique, Hôpital de l’archet, Centre Hospitalier Universitaire, Université Côte d’Azur, 151 Route de Saint-Antoine, 06200 Nice, France; (D.C.); (É.D.); (K.R.)
| | - Karine Risso
- Département de Médecine Infectiologique, Hôpital de l’archet, Centre Hospitalier Universitaire, Université Côte d’Azur, 151 Route de Saint-Antoine, 06200 Nice, France; (D.C.); (É.D.); (K.R.)
| | - Florence Askenazy-Gittard
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Hôpitaux Pédiatriques de Nice CHU-LENVAL, Centre Hospitalier Universitaire, Université Côte d’Azur, 57 Avenue de la Californie, 06200 Nice, France
| | - Charles Savoldelli
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 31 Avenue de Valombrose, 06100 Nice, France; (É.C.); (G.D.); (C.S.); (N.G.); (L.C.)
| | - Nicolas Guevara
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 31 Avenue de Valombrose, 06100 Nice, France; (É.C.); (G.D.); (C.S.); (N.G.); (L.C.)
| | - Philippe Robert
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Département d’Orthophonie de Nice (DON), UFR Médecine, Université Côte d’Azur, 06107 Nice, France
- Service Clinique Gériatrique du Cerveau et du Mouvement, Centre Hospitalier Universitaire de Nice, 06000 Nice, France
| | - Laurent Castillo
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 31 Avenue de Valombrose, 06100 Nice, France; (É.C.); (G.D.); (C.S.); (N.G.); (L.C.)
| | - Valeria Manera
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Département d’Orthophonie de Nice (DON), UFR Médecine, Université Côte d’Azur, 06107 Nice, France
| | - Auriane Gros
- Laboratoire CoBTeK, Université Côte d’Azur, 06100 Nice, France; (M.P.); (L.-É.D.); (A.P.); (F.A.-G.); (P.R.); (V.M.); (A.G.)
- Département d’Orthophonie de Nice (DON), UFR Médecine, Université Côte d’Azur, 06107 Nice, France
- Service Clinique Gériatrique du Cerveau et du Mouvement, Centre Hospitalier Universitaire de Nice, 06000 Nice, France
| |
Collapse
|
4
|
Fiorentino J, Payne M, Cancian E, Plonka A, Dumas LÉ, Chirio D, Demonchy É, Risso K, Askenazy-Gittard F, Guevara N, Castillo L, Robert P, Manera V, Vandersteen C, Gros A. Correlations between Persistent Olfactory and Semantic Memory Disorders after SARS-CoV-2 Infection. Brain Sci 2022; 12:brainsci12060714. [PMID: 35741601 PMCID: PMC9221020 DOI: 10.3390/brainsci12060714] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 05/20/2022] [Accepted: 05/27/2022] [Indexed: 12/11/2022] Open
Abstract
Background: One of the main symptoms of COVID-19 is hyposmia or even anosmia. Olfactory identification is most often affected. In addition, some cognitive disorders tend to appear following the infection, particularly regarding executive functions, attention, and memory. Olfaction, and especially olfactory identification, is related to semantic memory which manages general knowledge about the world. The main objective of this study was to determine whether semantic memory is impaired in case of persistent post COVID-19 olfactory disorders. Methods: 84 patients (average age of 42.8 ± 13.6 years) with post COVID-19 olfactory loss were included after consulting to the ENT department. The clinical evaluation was carried out with the Pyramid and Palm Tree Test, the word-retrieval task from the Grémots, the Sniffin’ Sticks Test and the Computerised Olfactory Test for the Diagnosis of Alzheimer’s Disease. Results: Semantic memory was impaired in 20% (n = 17) of patients, especially in the 19–39 age-group. The olfactory threshold was only significantly correlated with the semantic memory scores. Conclusions: Similar to all cognitive disorders, semantic disorders can have a negative impact on quality of life if left untreated. It is essential to carry out specific assessments of post COVID-19 patients to accurately determine their disorders and to put in place the best possible rehabilitation, such as speech and language therapy, to avoid quality-of-life impairment.
Collapse
Affiliation(s)
- Julie Fiorentino
- Département d’Orthophonie de Nice, Faculté de Médecine de Nice, 06107 Nice, France; (M.P.); (A.P.); (P.R.); (V.M.); (A.G.)
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
- Correspondence: ; Tel.: +33-674217791
| | - Magali Payne
- Département d’Orthophonie de Nice, Faculté de Médecine de Nice, 06107 Nice, France; (M.P.); (A.P.); (P.R.); (V.M.); (A.G.)
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
| | - Elisa Cancian
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 06100 Nice, France;
| | - Alexandra Plonka
- Département d’Orthophonie de Nice, Faculté de Médecine de Nice, 06107 Nice, France; (M.P.); (A.P.); (P.R.); (V.M.); (A.G.)
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
- Institut NeuroMod, Université Côté d’Azur, 06902 Sophia-Antipolis, France; (N.G.); (L.C.)
| | - Louise-Émilie Dumas
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
- Hôpitaux Pédiatriques de Nice CHU-LENVAL, 57 Avenue de la Californie, Centre Hospitalier Universitaire, Université Côte d’Azur, 06200 Nice, France
| | - David Chirio
- Département de Médecine Infectiologique, Hôpital de l’Archet, 151 Route de Saint-Antoine, Centre Hospitalier Universitaire, Université Côte d’Azur, 06200 Nice, France; (D.C.); (É.D.); (K.R.)
| | - Élisa Demonchy
- Département de Médecine Infectiologique, Hôpital de l’Archet, 151 Route de Saint-Antoine, Centre Hospitalier Universitaire, Université Côte d’Azur, 06200 Nice, France; (D.C.); (É.D.); (K.R.)
| | - Karine Risso
- Département de Médecine Infectiologique, Hôpital de l’Archet, 151 Route de Saint-Antoine, Centre Hospitalier Universitaire, Université Côte d’Azur, 06200 Nice, France; (D.C.); (É.D.); (K.R.)
| | - Florence Askenazy-Gittard
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
- Hôpitaux Pédiatriques de Nice CHU-LENVAL, 57 Avenue de la Californie, Centre Hospitalier Universitaire, Université Côte d’Azur, 06200 Nice, France
| | - Nicolas Guevara
- Institut NeuroMod, Université Côté d’Azur, 06902 Sophia-Antipolis, France; (N.G.); (L.C.)
| | - Laurent Castillo
- Institut NeuroMod, Université Côté d’Azur, 06902 Sophia-Antipolis, France; (N.G.); (L.C.)
| | - Philippe Robert
- Département d’Orthophonie de Nice, Faculté de Médecine de Nice, 06107 Nice, France; (M.P.); (A.P.); (P.R.); (V.M.); (A.G.)
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
| | - Valeria Manera
- Département d’Orthophonie de Nice, Faculté de Médecine de Nice, 06107 Nice, France; (M.P.); (A.P.); (P.R.); (V.M.); (A.G.)
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
| | - Clair Vandersteen
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
- Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d’Azur, 06100 Nice, France;
| | - Auriane Gros
- Département d’Orthophonie de Nice, Faculté de Médecine de Nice, 06107 Nice, France; (M.P.); (A.P.); (P.R.); (V.M.); (A.G.)
- Laboratoire CoBTeK, Institut Claude Pompidou, Université Côte d’Azur, 06100 Nice, France; (L.-É.D.); (F.A.-G.); (C.V.)
| |
Collapse
|
5
|
Vandersteen C, Payne M, Dumas LÉ, Plonka A, D'Andréa G, Chirio D, Demonchy É, Risso K, Robert P, Fernandez X, Askenazy-Gittard F, Savoldelli C, Guevara N, Castillo L, Manera V, Gros A. What about using sniffin' sticks 12 items test to screen post-COVID-19 olfactory disorders? Eur Arch Otorhinolaryngol 2021; 279:3477-3484. [PMID: 34716806 PMCID: PMC8556789 DOI: 10.1007/s00405-021-07148-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 10/18/2021] [Indexed: 01/02/2023]
Abstract
Background Post-COVID-19 Olfactory impairment has a negative impact on quality of life. The Sniffin Sticks test 12 items (SST-12) can be used in quick olfactory disorders screening. Its evaluation in a post-covid-19 situation was the main objective of this work. Methods All patient impaired with a post-COVID olfactory loss were included while consulting to the ENT department. The clinical examination included an olfaction recovery self-assessment (VAS), a nasofibroscopy, a quality of life (QoL) assessment, the complete Sniffin’ Sticks Test (SST), and the SST-12. Results Among the 54 patients included, 92% (n = 50) were correctly screened as olfactory impaired by SST-12. We report excellent correlations between SST-12 and SST (rho (52) = 0.98, p < 0.001), QoL(rho(52) = 0.33 p = 0.016), or VAS (rho(52) = 0.49, p < 0.001) assessments. Conclusions SST-12 is a quick and reliable tool to screen large-scale population of post-COVID-19 olfactory impaired patients and could be used in a general daily clinical practice.
Collapse
Affiliation(s)
- Clair Vandersteen
- Institut Universitaire de La Face Et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France. .,Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France.
| | - Magali Payne
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France.,Université Côte d'Azur, Département d'Orthophonie de Nice, UFR Medecine, Nice, France
| | - Louise-Émilie Dumas
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France.,Hôpitaux Pédiatriques de Nice CHU-LENVAL, Centre Hospitalier Universitaire, Université Côte d'Azur, 57 Avenue de la Californie, 06200, Nice, Alpes-Maritimes, France
| | - Alexandra Plonka
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France.,Institut NeuroMod, INRIA Centre de Recherche Sophia Antipolis, Université Côte d'Azur, 2004 Route des Lucioles, 06902, Sophia Antipolis, Alpes-Maritimes, France
| | - Grégoire D'Andréa
- Institut Universitaire de La Face Et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
| | - David Chirio
- Département de Médecine Infectiologique, Hôpital de L'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, 151 route de Saint-Antoine, 06200, Nice, Alpes-Maritimes, France
| | - Élisa Demonchy
- Département de Médecine Infectiologique, Hôpital de L'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, 151 route de Saint-Antoine, 06200, Nice, Alpes-Maritimes, France
| | - Karine Risso
- Département de Médecine Infectiologique, Hôpital de L'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, 151 route de Saint-Antoine, 06200, Nice, Alpes-Maritimes, France
| | - Philippe Robert
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France
| | - Xavier Fernandez
- Institut de Chimie de Nice, Université Côte d'Azur, Nice, Alpes-Maritimes, France
| | - Florence Askenazy-Gittard
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France
| | - Charles Savoldelli
- Institut Universitaire de La Face Et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
| | - Nicolas Guevara
- Institut Universitaire de La Face Et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
| | - Laurent Castillo
- Institut Universitaire de La Face Et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
| | - Valeria Manera
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France.,Institut NeuroMod, INRIA Centre de Recherche Sophia Antipolis, Université Côte d'Azur, 2004 Route des Lucioles, 06902, Sophia Antipolis, Alpes-Maritimes, France
| | - Auriane Gros
- Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire CoBTeK, Service Clinique Gériatrique du Cerveau Et du Mouvement, Nice, France.,Université Côte d'Azur, Département d'Orthophonie de Nice, UFR Medecine, Nice, France
| |
Collapse
|
6
|
Courjon J, Contenti J, Demonchy E, Levraut J, Barbry P, Rios G, Dellamonica J, Chirio D, Bonnefoy C, Giordanengo V, Carles M. COVID-19 patients age, comorbidity profiles and clinical presentation related to the SARS-CoV-2 UK-variant spread in the Southeast of France. Sci Rep 2021; 11:18456. [PMID: 34531412 PMCID: PMC8446095 DOI: 10.1038/s41598-021-95067-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 07/20/2021] [Indexed: 12/13/2022] Open
Abstract
The variant 20I/501Y.V1, associated to a higher risk of transmissibility, emerged in Nice city (Southeast of France, French Riviera) during January 2021. The pandemic has resumed late December 2020 in this area. A high incidence rate together with a fast turn-over of the main circulating variants, provided us the opportunity to analyze modifications in clinical profile and outcome traits. We performed an observational study in the University hospital of Nice from December 2020 to February 2021. We analyzed data of sequencing of SARS-CoV-2 from the sewage collector and PCR screening from all positive samples at the hospital. Then, we described the characteristics of all COVID-19 patients admitted in the emergency department (ED) (n = 1247) and those hospitalized in the infectious diseases ward or ICU (n = 232). The UK-variant was absent in this area in December, then increasingly spread in January representing 59% of the PCR screening performed mid-February. The rate of patients over 65 years admitted to the ED decreased from 63 to 50% (p = 0.001). The mean age of hospitalized patients in the infectious diseases ward decreased from 70.7 to 59.2 (p < 0.001) while the proportion of patients without comorbidity increased from 16 to 42% (p = 0.007). Spread of the UK-variant in the Southeast of France affects younger and healthier patients.
Collapse
Affiliation(s)
- Johan Courjon
- Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France. .,Université Côte d'Azur, Inserm, U1065, C3M, Nice, France.
| | - Julie Contenti
- Université Côte d'Azur, Inserm, U1065, C3M, Nice, France.,Emergency Department, Université Côte d'Azur, CHU Nice, Nice, France
| | - Elisa Demonchy
- Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France
| | - Jacques Levraut
- Emergency Department, Université Côte d'Azur, CHU Nice, Nice, France
| | - Pascal Barbry
- Institut de Pharmacologie Moleculaire et Cellulaire, UMR7275 CNRS/UNS, Valbonne, France
| | - Géraldine Rios
- Institut de Pharmacologie Moleculaire et Cellulaire, UMR7275 CNRS/UNS, Valbonne, France
| | - Jean Dellamonica
- Medical Intensive Care Unit Department, Université Côte d'Azur, CHU Nice, Nice, France
| | - David Chirio
- Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France
| | | | - Valérie Giordanengo
- Université Côte d'Azur, Inserm, U1065, C3M, Nice, France.,Virology Department, Université Côte d'Azur, CHU Nice, Nice, France
| | - Michel Carles
- Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France.,Université Côte d'Azur, Inserm, U1065, C3M, Nice, France
| |
Collapse
|
7
|
Vandersteen C, Payne M, Dumas LE, Metelkina-Fernandez V, Plonka A, Chirio D, Demonchy E, Risso K, Askenazy-Gittard F, Guevara N, Castillo L, Manera V, Gros A. Persistent olfactory complaints after COVID-19: a new interpretation of the psychophysical olfactory scores. RHINOL 2021. [DOI: 10.4193/rhinol/21.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Background: Sudden olfactory loss is a major symptom of SARS-CoV-2 infection and has a negative impact on daily life quality. Almost 80% of disorders regress spontaneously. No precise characterization of the medium- and long-term olfactory symptoms has been carried out yet, apart from self-assessments. The main objective of this work was to characterize persistent smell disorders in this population. Methodology: Consecutive patients consulting to the ENT department with post-Covid19 olfactory loss were included. The clinical examination included an analog scale for the self-assessment of olfactory recovery), a nasofibroscopy, the Sniffin’ Stick Test and the short version of the Questionnaire of olfactory disorders. Results: Among the 34 patients included, based on the Sniffin’ Sticks Test, 29.4% (n=10) could be classified as normosmic, 55.9% (n=19) as hyposmic and 14.7% (n=5) as functional anosmic). Only olfactory identification impairment was significantly correlated with olfactory complaint and daily anxiety and annoyance related to lack of olfaction recovery. This identification disorder seemed to worsen over time. Conclusions: It is crucial to assess odor identification disorders in case of persistent olfactory complaints after COVID-19. It is fundamental to target this disorder, as it does not improve spontaneously and negatively impact quality of life.
Collapse
|
8
|
Durand C, Kouchit Y, Prots L, Degand N, Dellamonica P, Demonchy E, Chirio D. A case of infective endocarditis caused by Arthrobacter woluwensis. Eur J Clin Microbiol Infect Dis 2021; 40:1329-1331. [PMID: 33432493 DOI: 10.1007/s10096-021-04154-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2020] [Accepted: 01/07/2021] [Indexed: 10/22/2022]
Abstract
Corynebacteria are rare causative agents of infective endocarditis. This is a reported case of a destructive aorto-mitral infective endocarditis caused by Arthrobacter woluwensis. Microbial identification was achieved by 16S rRNA polymerase chain reaction on valve tissue samples. Outcome was favorable after surgical valve replacement and 4-week antibiotic treatment.
Collapse
Affiliation(s)
- Claire Durand
- Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
| | - Yanis Kouchit
- Médecine interne, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Laurence Prots
- Bactériologie, Laboratoire de Biologie Médicale Cerballiance Saint-Laurent Centre, Saint-Laurent du Var, France
| | - Nicolas Degand
- Laboratoire de Bactériologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | | | - Elisa Demonchy
- Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | - David Chirio
- Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| |
Collapse
|
9
|
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabié A, Chirouze C, Drobacheff-Thiébaut C, Foltzer A, Bouiller K, Hustache-Mathieu L, Lepiller Q, Bozon F, Babre O, Brunel AS, Muret P, Chevalier E, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Aumeran C, Baud O, Corbin V, Goncalvez E, Mirand A, brebion A, Henquell C, Lamaury I, Fabre I, Curlier E, Ouissa R, Herrmann-Storck C, Tressieres B, Receveur MC, Boulard F, Daniel C, Clavel C, Roger PM, Markowicz S, Chellum Rungen N, Merrien D, Perré P, Guimard T, Bollangier O, Leautez S, Morrier M, Laine L, Boucher D, Point P, Cotte L, Ader F, Becker A, Boibieux A, Brochier C, Brunel-Dalmas F, Cannesson O, Chiarello P, Chidiac C, Degroodt S, Ferry T, Godinot M, Livrozet JM, Makhloufi D, Miailhes P, Perpoint T, Perry M, Pouderoux C, Roux S, Triffault-Fillit C, Valour F, Charre C, Icard V, Tardy JC, Trabaud MA, Ravaux I, Ménard A, Belkhir AY, Colson P, Dhiver C, Madrid A, Martin-Degioanni M, Meddeb L, Mokhtari M, Motte A, Raoux A, Toméi C, Tissot-Dupont H, Poizot-Martin I, Brégigeon S, Zaegel-Faucher O, Obry-Roguet V, Laroche H, Orticoni M, Soavi MJ, Ressiot E, Ducassou MJ, Jaquet I, Galie S, Colson H, Ritleng AS, Ivanova A, Debreux C, Lions C, Rojas-Rojas T, Cabié A, Abel S, Bavay J, Bigeard B, Cabras O, Cuzin L, Dupin de Majoubert R, Fagour L, Guitteaud K, Marquise A, Najioullah F, Pierre-François S, Pasquier J, Richard P, Rome K, Turmel JM, Varache C, Atoui N, Bistoquet M, Delaporte E, Le Moing V, Makinson A, Meftah N, Merle de Boever C, Montes B, Montoya Ferrer A, Tuaillon E, Reynes J, Lefèvre B, Jeanmaire E, Hénard S, Frentiu E, Charmillon A, Legoff A, Tissot N, André M, Boyer L, Bouillon MP, Delestan M, Goehringer F, Bevilacqua S, Rabaud C, May T, Raffi F, Allavena C, Aubry O, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-Cartier C, Deschanvres C, Gaborit BJ, Grégoire A, Grégoire M, Grossi O, Guéry R, Jovelin T, Lefebvre M, Le Turnier P, Lecomte R, Morineau P, Reliquet V, Sécher S, Cavellec M, Paredes E, Soria A, Ferré V, André-Garnier E, Rodallec A, Pugliese P, Breaud S, Ceppi C, Chirio D, Cua E, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Garraffo R, Michelangeli C, Mondain V, Naqvi A, Oran N, Perbost I, Carles M, Klotz C, Maka A, Pradier C, Prouvost-Keller B, Risso K, Rio V, Rosenthal E, Touitou I, Wehrlen-Pugliese S, Zouzou G, Hocqueloux L, Prazuck T, Gubavu C, Sève A, Giaché S, Rzepecki V, Colin M, Boulard C, Thomas G, Cheret A, Goujard C, Quertainmont Y, Teicher E, Lerolle N, Jaureguiberry S, Colarino R, Deradji O, Castro A, Barrail-Tran A, Yazdanpanah Y, Landman R, Joly V, Ghosn J, Rioux C, Lariven S, Gervais A, Lescure FX, Matheron S, Louni F, Julia Z, Le GAC S, Charpentier C, Descamps D, Peytavin G, Duvivier C, Aguilar C, Alby-Laurent F, Amazzough K, Benabdelmoumen G, Bossi P, Cessot G, Charlier C, Consigny PH, Jidar K, Lafont E, Lanternier F, Leporrier J, Lortholary O, Louisin C, Lourenco J, Parize P, Pilmis B, Rouzaud C, Touam F, Valantin MA, Tubiana R, Agher R, Seang S, Schneider L, PaLich R, Blanc C, Katlama C, Bani-Sadr F, Berger JL, N’Guyen Y, Lambert D, Kmiec I, Hentzien M, Brunet A, Romaru J, Marty H, Brodard V, Arvieux C, Tattevin P, Revest M, Souala F, Baldeyrou M, Patrat-Delon S, Chapplain JM, Benezit F, Dupont M, Poinot M, Maillard A, Pronier C, Lemaitre F, Morlat C, Poisson-Vannier M, Jovelin T, Sinteff JP, Gagneux-Brunon A, Botelho-Nevers E, Frésard A, Ronat V, Lucht F, Rey D, Fischer P, Partisani M, Cheneau C, Priester M, Mélounou C, Bernard-Henry C, de Mautort E, Fafi-Kremer S, Delobel P, Alvarez M, Biezunski N, Debard A, Delpierre C, Gaube G, Lansalot P, Lelièvre L, Marcel M, Martin-Blondel G, Piffaut M, Porte L, Saune K, Robineau O, Ajana F, Aïssi E, Alcaraz I, Alidjinou E, Baclet V, Bocket L, Boucher A, Digumber M, Huleux T, Lafon-Desmurs B, Meybeck A, Pradier M, Tetart M, Thill P, Viget N, Valette M. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clin Infect Dis 2021; 73:e3266-e3274. [DOI: 10.1093/cid/ciaa1940] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 01/01/2021] [Indexed: 01/15/2023] Open
Abstract
Abstract
Background
The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort.
Methods
This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors.
Results
From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018.
Conclusions
A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM.
Clinical Trials Registration. NCT02898987.
Collapse
Affiliation(s)
- Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Lyon, France
| | - Laurent Hocqueloux
- Department of Infectious Diseases, Centre Hospitalier Régional d’Orléans – La Source, Orléans, France
| | - Maeva Lefebvre
- Department of Infectious Diseases, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes; Centre d’Investigation Clinique (CIC) 1413, INSERM, Nantes, France
| | - Pierre Pradat
- Center for Clinical Research, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Isabelle Poizot-Martin
- Immuno-Hematology Clinic, Assistance Publique–Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, Aix-MarseilleUniversity–Inserm–Institut de Recherche pour le Développement (IRD), Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l’Archet, Nice, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg
| | - André Cabié
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Martinique, Fort de France, Université des Antilles EA4537, Fort de France, INSERM CIC1424, Fort-de-France, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Ferrari E, Sartre B, Squara F, Contenti J, Occelli C, Lemoel F, Levraut J, Doyen D, Dellamonica J, Mondain V, Chirio D, Risso K, Cua E, Orban JC, Ichai C, Labbaoui M, Mossaz B, Moceri P, Appert-Flory A, Fischer F, Toulon P. High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019. J Am Heart Assoc 2020; 9:e017773. [PMID: 32972320 PMCID: PMC7763401 DOI: 10.1161/jaha.120.017773] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Background Recent literature reports a strong thrombotic tendency in patients hospitalized for a coronavirus disease 2019 (COVID-19) infection. This characteristic is unusual and seems specific to COVID-19 infections, especially in their severe form. Viral infections can trigger acquired thrombophilia, which can then lead to thrombotic complications. We investigate for the presence of acquired thrombophilia, which could participate in this phenomenon, and report its prevalence. We also wonder if these thrombophilias participate in the bad prognosis of severe COVID-19 infections. Methods and Results In 89 consecutive patients hospitalized for COVID-19 infection, we found a 20% prevalence of PS (protein S) deficiency and a high (ie, 72%) prevalence of antiphospholipid antibodies: mainly lupus anticoagulant. The presence of PS deficiency or antiphospholipid antibodies was not linked with a prolonged activated partial thromboplastin time nor with D-dimer, fibrinogen, or CRP (C-reactive protein) concentrations. These coagulation abnormalities are also not linked with thrombotic clinical events occurring during hospitalization nor with mortality. Conclusions We assess a high prevalence of positive tests detecting thrombophilia in COVID-19 infections. However, in our series, these acquired thrombophilias are not correlated with the severity of the disease nor with the occurrence of thrombotic events. Albeit the strong thrombotic tendency in COVID-19 infections, the presence of frequent acquired thrombophilia may be part of the inflammation storm of COVID-19 and should not systematically modify our strategy on prophylactic anticoagulant treatment, which is already revised upwards in this pathological condition. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04335162.
Collapse
Affiliation(s)
- Emile Ferrari
- Department of Cardiology University Hospital of Nice France
| | | | - Fabien Squara
- Department of Cardiology University Hospital of Nice France
| | - Julie Contenti
- Department of Emergency University Hospital of Nice France
| | - Celine Occelli
- Department of Emergency University Hospital of Nice France
| | - Fabien Lemoel
- Department of Emergency University Hospital of Nice France
| | | | - Denis Doyen
- Department of Intensive Care 1 University Hospital of Nice France
| | - Jean Dellamonica
- Department of Intensive Care 1 University Hospital of Nice France
| | - Veronique Mondain
- Department of Infectious Diseases University Hospital of Nice France
| | - David Chirio
- Department of Infectious Diseases University Hospital of Nice France
| | - Karine Risso
- Department of Infectious Diseases University Hospital of Nice France
| | - Eric Cua
- Department of Infectious Diseases University Hospital of Nice France
| | | | - Carole Ichai
- Department of Intensive Care 2 University Hospital of Nice France
| | | | | | - Pamela Moceri
- Department of Cardiology University Hospital of Nice France
| | | | | | - Pierre Toulon
- Hematology Laboratory University Hospital of Nice France
| |
Collapse
|
11
|
Abstract
In 2018, yellow fever with hepatitis was diagnosed for 2 unvaccinated travelers returning to France from Brazil. Hepatitis persisted for >6 months; liver enzyme levels again increased 2 months after disease onset with no detection of yellow fever virus RNA or other pathogens. Persistent hepatitis with hepatic cytolysis rebound probably resulted from immune response.
Collapse
|
12
|
Denis B, Chirio D, Ponscarme D, Brichler S, Verdière NCD, Simon F, Molina J. Rebond cytolytique et hépatite persistante chez deux voyageurs français ayant contracté une fièvre jaune (FJ) au retour du Brésil. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Merindol J, Ferrero S, Jeandel P, Allouche J, Karsenti J, Risso K, Demonchy E, Chirio D. Une cryptococcose surprise. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Denis B, Chirio D, Ponscarme D, Brichler S, Colin de Verdière N, Simon F, Molina JM. Hepatitis Rebound after Infection with Yellow Fever Virus. Emerg Infect Dis 2019. [DOI: 10.3201/eid2506.190096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
15
|
Grine G, Lotte R, Chirio D, Chevalier A, Raoult D, Drancourt M, Ruimy R. Co-culture of Methanobrevibacter smithii with enterobacteria during urinary infection. EBioMedicine 2019; 43:333-337. [PMID: 31072770 PMCID: PMC6558020 DOI: 10.1016/j.ebiom.2019.04.037] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Revised: 04/10/2019] [Accepted: 04/18/2019] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Urinary tract infections are known to be caused by bacteria, but the potential implications of archaea have never been studied in this context. METHODS In two different university hospital centres we used specific laboratory methods for the detection and culture of archaeal methanogens in 383 urine specimens prospectively collected for diagnosing urinary tract infection (UTI). FINDINGS Methanobrevibacter smithii was detected by quantitative PCR and sequencing in 34 (9%) of the specimens collected from 34 patients. Escherichia coli, Klebsiella pneumoniae, Enterobacter sp., Enterococcus faecium and mixed cultures were detected along with M. smithii in eighteen, six, three, one and six urine samples, respectively. Interestingly, using our specific culture method for methanogens, we also isolated M. smithii in 31 (91%) of the 34 PCR positive urine samples. Genotyping the 31 isolates using multispacer sequence typing revealed three different genotypes which have been previously reported in intestinal microbiota. Antibiotic susceptibility testing found the 31 isolates to be in vitro susceptible to metronidazole (MIC: 1 mg/L) but resistant to fosfomycin, sulfamethoxazole-trimethoprim, amoxicillin-clavulanate and ofloxacin, commonly used to treat bacterial UTI. Finally, 19 (54%) of the 34 patients in whose urine samples M. smithii was detected were diagnosed with UTIs, including cystitis, pyelonephritis and prostatitis. INTERPRETATION Our results show that M. smithii is part of the urinary microbiota of some individuals and could play a role in community-acquired UTI in association with enteric bacteria. FUND: This study was supported by IHU Méditerranée Infection, Marseille, France.
Collapse
Affiliation(s)
- Ghiles Grine
- IHU Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France; Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Hôpital de l'Archet II, Nice, France
| | - Romain Lotte
- Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Hôpital de l'Archet II, Nice, France; Université Côte d'Azur, Inserm, C3M, Nice, France; Inserm U1065, C3M, Equipe 6 « Virulence microbienne et signalisation inflammatoire », Bâtiment universitaire Archimède, Nice, France
| | - David Chirio
- Service de maladies infectieuses et tropicales, Centre Hospitalier Universitaire de Nice, Hôpital de l'Archet I, Nice, France
| | - Alicia Chevalier
- Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Hôpital de l'Archet II, Nice, France
| | - Didier Raoult
- Aix Marseille Université, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France
| | - Michel Drancourt
- Aix Marseille Université, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France
| | - Raymond Ruimy
- Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Hôpital de l'Archet II, Nice, France; Université Côte d'Azur, Inserm, C3M, Nice, France; Inserm U1065, C3M, Equipe 6 « Virulence microbienne et signalisation inflammatoire », Bâtiment universitaire Archimède, Nice, France.
| |
Collapse
|
16
|
Chirio D, Le Marechal M, Moceri P, de la Chapelle A, Chaillou-Optiz S, Mothes A, Foucault C, Maulin L, Parsaï C, Roger PM, Demonchy E. Factors associated with unfavorable outcome in a multicenter audit of 100 infective endocarditis. Eur J Clin Microbiol Infect Dis 2018; 38:109-115. [PMID: 30324540 DOI: 10.1007/s10096-018-3401-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2018] [Accepted: 10/08/2018] [Indexed: 12/17/2022]
Abstract
We aimed to identify factors associated with unfavorable outcome in patients treated for infective endocarditis (IE), with a focus on departure from European guidelines. We conducted a retrospective audit of all adult patients treated for endocarditis during a 1-year period across a regional network of nine care centers in the south-east of France. Medical records were reviewed regarding patient and infection characteristics, antibiotic therapy, outcome, and compliance to the European Society of Cardiology guidelines. Antibiotic treatment appropriateness was evaluated regarding molecule, dosage, and duration, according to guidelines. Primary endpoint was the assessment of factors associated with unfavorable outcome, defined as in-hospital mortality or IE relapse at 1-year follow-up. Secondary endpoints were intensive care admission, iatrogenic events, and nosocomial infections that occurred during hospital stay. One hundred patients were included. Median age was 71 years old. Twenty-two patients died and IE relapse occurred in two patients, representing 24 patients with unfavorable outcome. Overall, antibiotic treatment was deemed appropriate in 28 cases. Thirty-three patients required intensive care, 34 iatrogenic events were found, including 19 acute kidney injuries, and 13 nosocomial infections occurred during care. Using a logistic regression, factors associated with unfavorable outcome were admission in the intensive care unit (adjusted odd ratio 7.26 [1.8-29.28]; p = 0.005), new-onset nosocomial infection (adjusted odd ratio 8.83 [1.42-54.6]; p = 0.019), and age > 71 years old (adjusted odd ratio 11.2 [2.76-46.17]; p < 0.001). Departure from guidelines was frequent but not related to unfavorable outcome in our study. Only intensive care, age, and nosocomial infections were associated with mortality and relapse. Iatrogenic events were numerous, with no impact on outcome.
Collapse
Affiliation(s)
- David Chirio
- Infectiologie, Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, 151 Route de Saint Antoine, 06200, Nice, France.
| | - Marion Le Marechal
- Infectiologie, Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, 151 Route de Saint Antoine, 06200, Nice, France
| | - Pamela Moceri
- Cardiologie, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Arnaud de la Chapelle
- Réanimation cardio-thoracique, Institut Arnault Tzanck, Saint-Laurent-du-Var, France
| | | | - Anaïs Mothes
- Médecine Interne et Polyvalente, Centre Hospitalier de la Dracénie, Draguignan, France
| | - Cédric Foucault
- Médecine Polyvalente et Infectiologie, Centre Hospitalier d'Hyères, Hyères, France
| | - Laurence Maulin
- Infectiologie, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
| | | | - Pierre-Marie Roger
- Infectiologie, Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, 151 Route de Saint Antoine, 06200, Nice, France
| | - Elisa Demonchy
- Infectiologie, Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, 151 Route de Saint Antoine, 06200, Nice, France
| |
Collapse
|
17
|
Nkamga VD, Lotte R, Chirio D, Lonjon M, Roger PM, Drancourt M, Ruimy R. Methanobrevibacter oralis detected along with Aggregatibacter actinomycetemcomitans in a series of community-acquired brain abscesses. Clin Microbiol Infect 2017; 24:207-208. [PMID: 28882726 DOI: 10.1016/j.cmi.2017.08.021] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Revised: 08/25/2017] [Accepted: 08/26/2017] [Indexed: 11/30/2022]
Affiliation(s)
- V D Nkamga
- Unité de recherche sur les maladies infectieuses tropicales et émergentes, Marseille, France; Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Nice, France
| | - R Lotte
- Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Nice, France; Université Nice Côte d'Azur, Inserm, C3M, Nice, France; INSERM U1065, C3M, Team 6, "Bacterial Toxins in Host Pathogen Interactions", Bâtiment universitaire Archimed, Nice, France
| | - D Chirio
- Service de maladies infectieuses et tropicales, Centre Hospitalier Universitaire de Nice, Nice, France
| | - M Lonjon
- Unité de Neurochirurgie, Centre Hospitalier Universitaire de Nice, Nice, France
| | - P-M Roger
- Service de maladies infectieuses et tropicales, Centre Hospitalier Universitaire de Nice, Nice, France
| | - M Drancourt
- Unité de recherche sur les maladies infectieuses tropicales et émergentes, Marseille, France
| | - R Ruimy
- Laboratoire de bactériologie, Centre Hospitalier Universitaire de Nice, Nice, France; Université Nice Côte d'Azur, Inserm, C3M, Nice, France; INSERM U1065, C3M, Team 6, "Bacterial Toxins in Host Pathogen Interactions", Bâtiment universitaire Archimed, Nice, France.
| |
Collapse
|
18
|
Courjon J, Demonchy E, Chirio D, Risso K, Ruimy R, Roger P. Bactériémies communautaires : quelle est la meilleure combinaison antibiotique ? Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Mothes A, Léotard S, Nicolle I, Smets A, Chirio D, Rotomondo C, Tiger F, Del Giudice P, Perrin C, Néri D, Foucault C, Della Guardia M, Hyvernat H, Roger PM. Community-acquired pneumonia and positive urinary antigen tests: Factors associated with targeted antibiotic therapy. Med Mal Infect 2016; 46:365-371. [DOI: 10.1016/j.medmal.2016.05.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Revised: 01/28/2016] [Accepted: 05/13/2016] [Indexed: 11/30/2022]
|
20
|
|
21
|
Chirio D, Demonchy E, Martis N, Moceri P, Mothes A, Foucault C, Chapelle ADL, Chaillou S, Pietri P, Tiger F, Fuzibet J, Roger P. Endocardites infectieuses : audit régional sur la qualité de prise en charge. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Chirio D, Demonchy E, Martis N, Moceri P, Mothes A, Foucault C, De la Chapelle A, Chaillou S, Pietri P, Roger P. ENDO-08 - Endocardites infectieuses : audit régional sur la qualité de prise en charge. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30377-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Chirio D, Demonchy E, Cua E, Leroy S, Litrico S, Roger P. Un germe exceptionnel pour une complication classique d’une maladie rare. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Biasibetti E, Valazza A, Battaglia L, Gallarate M, Peira E, Chirio D, Muntoni E, Panciani P, Riganti C, Annovazzi L, Caldera V, Schiffer D, Lanotte M, Capucchio M. Experimental glioblastoma in the fisher rat model: Treatment with a biocompatible system as carrier of methotrexate. J Comp Pathol 2015. [DOI: 10.1016/j.jcpa.2014.10.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Chirio D, Demonchy E, Laffon M, Fournier-Mehouas M, Roger P, Ollier L, Piche T, Dellamonica P. Syndrome de Parsonage Turner et hépatite E : à propos de deux cas. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
Chirio D, Richez V, Vinti H, Dellamonica J, Rohrlich P. Un myélome dératé. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Chirio D, Boyer S, Denis E, Re D, Zahreddine K, Quinsat D. Tophus goutteux du rachis cervical : un cou à ne pas rater. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Boyer S, Queyrel V, Chirio D, Gelsi E, Tieulie N, Fuzibet J. Malformations artério-veineuses symptomatiques au cours de la maladie de Rendu-Osler et bevacizumab : un enjeu thérapeutique majeur. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Cirillo S, Giacomotti MM, Leggieri A, Bordino F, Chirio D, Gallarate M. TCH-009 Development of a Stable Nystatin Oral Suspension to Overcome Shortages of the Commercial Medicine. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
30
|
Bussano R, Chirio D, Costa L, Turci F, Trotta M. Preparation and Characterization of Insulin-Loaded Lipid-Based Microspheres Generated by Electrospray. J DISPER SCI TECHNOL 2011. [DOI: 10.1080/01932691.2010.505876] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
|
32
|
|
33
|
|
34
|
Peira E, Chirio D, Carlotti M, Spagnolo R, Trotta M. Formulation studies of microemulsions for topical applications of acyclovir. J Drug Deliv Sci Technol 2009. [DOI: 10.1016/s1773-2247(09)50035-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Peira E, Trotta M, Carlotti M, Gallarate M, Chirio D. Elastic positively-charged liposomes for topical administration of acyclovir. J Drug Deliv Sci Technol 2007. [DOI: 10.1016/s1773-2247(07)50049-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|